Beijing Luzhu Biotechnology Co., Ltd. (2480.HK)

26,800 -0,300 (-1,11%) Alla chiusura: 11:34AM HKT

Beijing Luzhu Biotechnology Co., Ltd.

No. 3 Guangtong Street
Industrial Development Zone Tongzhou District
Beijing
China
86 10 6156 8561
https://luzhubiotech.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 133

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jian Kong	Co-Founder, GM, CEO, Chief Scientist & Chairman	772,39k	N/D	1964
Ms. Xianmin Jiang	Co-Founder, Deputy GM, Chief Medical Officer & Vice-Chairlady	579,83k	N/D	1963
Ms. Yanping Zhang	Co-Founder, Deputy GM & Executive Director	580,91k	N/D	1963
Ms. Zheng Liu	Chief Financial Officer	N/D	N/D	1987
Ms. Ling Peng	CTO & Supervisor	N/D	N/D	1981
Mr. Chaowei Han	Head of Manufacturing & Engineering	N/D	N/D	1975
Mr. Siyu Liu	Secretary of Board & Joint Company Secretary	N/D	N/D	1991
Ms. Wing Yan Yuen FCIS, FCS	Joint Company Secretary	N/D	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine; K3, a recombinant human anti-TNF-a monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma. The company's pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of chickenpox caused by varicella-zoster virus; Recombinant Rabies vaccine to prevent rabies in humans; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 to treat B cell lymphoma. It also offers immunoreagent enzyme-linked kits, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and haemophilus influenzae Type b polysaccharide IgG antibody detection kits. The company also provides out-licensed products, including influenzae type b conjugate, Group ACYW135 meningococcal polysaccharide, Group A and C meningococcal - haemophilus influenzae type b conjugate, Group A and C meningococcal polysaccharide, and Group A and C meningococcal polysaccharide conjugate vaccine products. The company has a strategic cooperation with Tianjin Ringpu Bio-Technology Co., Ltd. to develop monoclonal antibody drugs and genetically engineered vaccines for pets. Beijing Luzhu Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.

Governance aziendale

L'ISS Governance QualityScore di Beijing Luzhu Biotechnology Co., Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.